Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy.

ABSTRACT:

Background

Dopamine transporter single photon-emission computed tomography (DAT-SPECT) is the strongest risk factor for phenoconversion in patients with idiopathic rapid eye movement (REM)-sleep behavior disorder (iRBD). However, it might be used as a second-line stratification tool in clinical trials, because it is expensive and mini-invasive.

Objective

Aim of the study is to investigate whether other cost-effective and non-invasive biomarkers may be proposed as first-line stratification tools.

Methods

Forty-seven consecutive iRBD patients (68.53 ± 7.16 years, 40 males) underwent baseline clinical and neuropsychological assessment, olfaction test, resting electroencephalogram (EEG), and DAT-SPECT. All patients underwent 6 month-based clinical follow-up to investigate

SUBMITTER: Arnaldi D 

PROVIDER: S-EPMC9292414 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature